Damora Therapeutics, Inc. (DMRA)
20.90
-0.01
(-0.05%)
USD |
NASDAQ |
Jun 09, 14:38
Damora Therapeutics SG&A Expense (Quarterly) : 7.034M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Spyre Therapeutics, Inc. | 15.23M |
| Incyte Corp. | 328.09M |
| ACADIA Pharmaceuticals, Inc. | 171.02M |
| Alnylam Pharmaceuticals, Inc. | 322.55M |
| Savara, Inc. | 15.57M |